GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cabio Biotech (Wuhan) Co Ltd (SHSE:688089) » Definitions » Stock Based Compensation

Cabio Biotech (Wuhan) Co (SHSE:688089) Stock Based Compensation : ¥0.0 Mil (TTM As of Sep. 2024)


View and export this data going back to 2019. Start your Free Trial

What is Cabio Biotech (Wuhan) Co Stock Based Compensation?

Cabio Biotech (Wuhan) Co's Stock Based Compensation for the three months ended in Sep. 2024 was ¥0.0 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 was ¥0.0 Mil.


Cabio Biotech (Wuhan) Co Stock Based Compensation Historical Data

The historical data trend for Cabio Biotech (Wuhan) Co's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cabio Biotech (Wuhan) Co Stock Based Compensation Chart

Cabio Biotech (Wuhan) Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cabio Biotech (Wuhan) Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cabio Biotech (Wuhan) Co Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥0.0 Mil.


Cabio Biotech (Wuhan) Co Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Cabio Biotech (Wuhan) Co's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Cabio Biotech (Wuhan) Co Business Description

Traded in Other Exchanges
N/A
Address
No. 999, Gaoxin Avenue, Donghu New Technology Development Zone, Wuhan, CHN, 430073
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Executives
Xiao Min senior management
Shang Yun Core technical personnel
Wang Hua Biao Directors, senior managers
Geng An Feng senior management
Du Bin Director
Yi Hua Rong senior management
Ma Tao senior management
Li Xiang Yu senior management
Wu Yu Jun Supervisors
Wang Zhi Ming senior management
Lu Shu Huan Core technical personnel
Yi De Wei Director

Cabio Biotech (Wuhan) Co Headlines

No Headlines